BioCryst Pharmaceuticals

Japan approved once-daily ORLADEYO for hereditary angioedema patients aged 2–12, making it the only oral pediatric prophylactic in that market and strengthening BioCryst's international growth runway. The company has begun US granule shipments and now has ORLADEYO cleared in over 45 countries, while Q2 revenue rose 34% to $218.3 million and cash totaled $354.0 million with positive free cash flow. Management left full-year ORLADEYO guidance unchanged and notes that commercial uptake in Japan depends on the National Health Insurance pricing process; recent revenue growth was also supported by a one-time € licensing payment for navenibart. BioCryst is shifting to an external-licensing R&D model and streamlining operations, which raises execution risk around pipeline assets and international launches. » More on finance.yahoo.com

BioCryst reported sustained profitability driven by hereditary angioedema drug Orladeyo and expects up to $645 million in sales for 2026, enabling management to fund further rare-disease deals without relying on equity raises. The company has already acquired Astria, adding late-stage candidate navenibart with pivotal data expected in 2027. Financial constraints remain, including negative shareholders' equity and about $822 million in term-loan and royalty obligations, leaving limited room for execution risk if Orladeyo growth slows or acquisitions disappoint. » More on finance.yahoo.com

The Japanese Ministry of Health has approved ORLADEYO (berotralstat) for prophylactic treatment of hereditary angioedema (HAE) in patients aged 2 to under 12 years. The oral granule formulation showed a consistent safety profile and was generally well tolerated in the APeX-P study of 29 children; the most common treatment-related adverse event was nasopharyngitis. BioCryst will launch the drug in Japan with distribution partner OrphanPacific after completion of pricing and reimbursement processes; approval applications for the same indication are pending with the EMA and Health Canada. » More on de.investing.com